Synthesis of Carboxamide‐Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

Synthesis of Carboxamide‐Containing Tranylcypromine Analogues as LSD1 (KDM1A) Inhibitors Targeting Acute Myeloid Leukemia

Published:2021-02-03 Issue:8 Volume:16 Page:1316-1324
ISSN:1860-7179
Container-title:ChemMedChem
language:en
Short-container-title:ChemMedChem

Author:

Teresa Borrello Maria¹^ORCID,Benelkebir Hanae¹,Lee Adam¹,Hin Tam Chak¹,Shafat Manar²,Rushworth Stuart A.²,Bowles Kristian M.²,Douglas Leon³,Duriez Patrick J.³,Bailey Sarah³,Crabb Simon J.³,Packham Graham³,Ganesan A.¹^ORCID

Affiliation:

1. School of Pharmacy University of East Anglia Norwich NR4 7TJ UK

2. Norwich Medical School University of East Anglia Norwich NR4 7TJ UK

3. Protein Core Facility and Cancer Sciences Cancer Research UK Centre and Experimental Cancer Medicines Centre University of Southampton Southampton General Hospital Southampton SO16 6YD UK

Publisher

Wiley

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics,Molecular Medicine,Drug Discovery,Biochemistry,Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cmdc.202000754

Reference23 articles.

1. Chemical and Biochemical Perspectives of Protein Lysine Methylation

2. Recent Progress in Histone Demethylase Inhibitors

3. Epigenetic drug discovery: a success story for cofactor interference

4. LSD1/KDM1A, a Gate-Keeper of Cancer Stemness and a Promising Therapeutic Target

5. Lysine-Specific Histone Demethylases Contribute to Cellular Differentiation and Carcinogenesis

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9‐dependent AML;HemaSphere;2024-05

2. A Quinquennial Review of Potent LSD1 Inhibitors Explored for the Treatment of Different Cancers, with Special Focus on SAR Studies;Current Medicinal Chemistry;2024-01

3. LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials;Frontiers in Pharmacology;2023-02-02

4. Tranylcypromine (TCP);Privileged Scaffolds in Drug Discovery;2023

5. Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present);European Journal of Medicinal Chemistry;2022-03